Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...

BNP Paribas Exane initiated coverage of Vertex (VERX) with an Outperform rating and $54 price target Stay Ahead of the Market: Discover ...